SISCAPA Assay Technologies

Executive Summary

SISCAPA Assay Technologies (SAT) is a US-based company specializing in precision protein measurement through its proprietary SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) platform. By integrating mass spectrometry with antibody-based enrichment, SAT overcomes the limitations of conventional immunoassays, offering high precision, sensitivity, and multiplexing capabilities. The company targets pharmaceutical and diagnostic partners for drug development, clinical trials, and biomarker validation. With a focus on pre-clinical and clinical applications, SAT is well-positioned to address the growing demand for reliable protein quantification in personalized medicine and translational research. Despite being in a pre-clinical stage, the company's technology has potential to disrupt the proteomics market by enabling reproducible and scalable assays that bridge the gap between discovery and clinical diagnostics. SAT's near-term outlook hinges on commercial partnerships and assay validation milestones. The company's SISCAPA platform has been referenced in scientific literature, suggesting credibility within the proteomics community. However, given its private status and lack of disclosed funding or revenue, the company remains early-stage with significant execution risk. Success will depend on securing pharma collaborations for drug development programs and expanding its assay menu to serve high-value biomarkers. If SAT can demonstrate robust multiplexing and sensitivity in regulated settings, it could become a key player in targeted proteomics. The next 12–24 months will be critical for establishing proof-of-concept and attracting strategic investment.

Upcoming Catalysts (preview)

• Q4 2026Pharma partnership for SISCAPA assay deployment in clinical trials40% success
• Q2 2027Launch of multiplexed biomarker panel for oncology30% success
• TBDSeries A funding round to scale operations50% success